United States securities and exchange commission logo





                          February 8, 2021

       Amro Albanna
       Chief Executive Officer
       Aditx Therapeutics, Inc.
       2569 Wyandotte St., Suite 101
       Mountain View, CA 94043

                                                        Re: Aditx Therapeutics,
Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed February 4,
2021
                                                            File No. 333-252711

       Dear Mr. Albanna:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact David
Gessert at 202-551-2326 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences